Household cost-of-illness of visceral leishmaniasis in Bihar, India

Tropical Medicine and International Health

Volumn 15, Issue SUPPL. 2, 2010, Pages 50-54

  Sundar, Shyam ^a   Arora, Rakesh ^a   Singh, S P ^a   Boelaert, Marleen ^b   Varghese, Beena ^c  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

Cost analysis; Cost of illness; Direct costs; Economic evaluation; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; ANTIMONY GLUCONATE; MILTEFOSINE;

AGE STRUCTURE; ENDEMISM; EPIDEMIOLOGY; HEALTH EXPENDITURE; HEALTH SERVICES; HOUSEHOLD EXPENDITURE; HOUSEHOLD INCOME; LEISHMANIASIS; NONGOVERNMENTAL ORGANIZATION; PUBLIC ACCESS; PUBLIC HEALTH; QUESTIONNAIRE SURVEY; SERVICE PROVISION;

ADULT; ARTICLE; DIAGNOSIS; DRUG COST; FEMALE; FOOD; HEALTH CARE COST; HOSPITALIZATION; HOUSEHOLD; HUMAN; INCOME; INDIA; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; QUESTIONNAIRE; SCREENING; VISCERAL LEISHMANIASIS; WORK;

ADOLESCENT; ADULT; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; SICK LEAVE; SOCIOECONOMIC FACTORS; TIME FACTORS; YOUNG ADULT;

BIHAR; INDIA;

EID: 77953185211     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02520.x     Document Type: Article

References (13)

1. Anoopa Sharma D, Bern C, Varghese B et al. (2006) The economic impact of visceral leishmaniasis on households in Bangladesh. Tropical Medicine and International Health 11, 757 764.
2. Bern C, Adler-Moore J, Berenguer J et al. (2006) Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases 43, 917 924.
3. Boelaert M, Meheus F, Sanchez A et al. (2009) The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Tropical Medicine and International Health 14, 1 6.
4. Bryceson A (2001) A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 6, 928 934.
5. Croft SL, Sundar S Fairlamb AH (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews 91, 111 126.
6. Meheus F, Boelaert M, Baltussen R Sundar S (2006) Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Tropical Medicine and International Health 11, 1715 1724.
7. Olliaro P Sundar S (2009) Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Tropical Medicine and International Health 14, 88 92.
8. Rijal S, Koirala S, Van der Stuyft P Boelaert M (2006) The economic burden of visceral leishmaniasis for households in Nepal. Transactions of the Royal Society of Tropical Medicine and Hygiene 100, 838 841.
9. Sundar S Murray HW (2005) Availability of miltefosine for the treatment of kala-azar in India. Bulletin of the World Health Organization 83, 394 395.
10. Sundar S, More DK, Singh MK et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases 31, 1104 1107.
11. Sundar S, Agrawal G, Madhukar R et al. (2001) Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. British Medical Journal 323, 419 422.
12. Sundar S, Chakravarty J, Rai VK et al. (2007) Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clinical Infectious Diseases 45, 556 561.
13. World Bank (2005) Bihar: Towards a Development Strategy. World Bank